Announcement PDF Market Announcement 3 October 2024 Immuron Limited (ASX: IMC) – Trading Halt Description The securities of Immuron Limited (‘IMC’) will be placed in trading halt at the request of IMC, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 7 October 2024 or when the announcement is released to the market. Issued by ASX Compliance 3 October 2024 ASX Limited Market Announcement 1/1 ASX Customer Service Centre 131 279 | asx.com.au 3 October 2024 Melissa Kostopoulos Compliance Adviser, Listings Compliance ASX Compliance Pty Ltd Level 50, South Tower, Rialto 525 Collins St Melbourne VIC 3000 By email: TradingHaltsMelbourne@asx.com.au ListingsComplianceMelbourne@asx.com.au Dear Melissa Request for Trading Halt - Immuron Limited In accordance with ASX Listing Rule 17.1, Immuron Limited (ASX: IMC; NASDAQ: IMRN) (the Company) requests an immediate trading halt in respect of its securities. This trading halt is requested to allow Immuron to analyse and interpret CampETEC Hyperimmune Bovine Colostrum (HBC) (clinicaltrials.gov/study/NCT06122870) clinical trial data prior to making an announcement. The Company requests that trading in its securities be halted until after the expected announcement is made or until the market opens on 7 October 2024, whichever is the earlier. The Company is not aware of any reason why this trading halt request should not be granted or of any other information necessary to inform the market about the trading halt. Please contact me if you require any further information. Yours sincerely Phillip Hains Company Secretary Immuron Limited ABN 80 063 114 045 www.immuron.com Australia: +61 3 8892 4854 USA and Canada: +1 (213) 817-5756